Featured Research

from universities, journals, and other organizations

How immune system peacefully co-exists with 'good' bacteria

Date:
May 22, 2013
Source:
Perelman School of Medicine at the University of Pennsylvania
Summary:
The human gut is loaded with helpful bacteria microbes, yet the immune system seemingly turns a blind eye. Now, researchers know how this friendly truce is kept intact. Innate lymphoid cells directly limit the response by inflammatory T cells to commensal bacteria in the gut of mice. Loss of this ILC function effectively puts the immune system on an extended war footing against the commensal bacteria a condition observed in multiple chronic inflammatory diseases.

Innate lymphoid cells in the intestine of healthy mice. A histologic section of intestinal tissue isolated from healthy Rag1-deficient mice stained to visualize innate lymphoid cells (RORgt-eGFP, green), intestinal epithelial cells (EpCAM, red) and nuclei (DAPI, blue).
Credit: Lance Peterson, Matthew Hepworth, David Artis and Gregory Sonnenberg. Perelman School of Medicine, University of Pennsylvania

The human gut is loaded with commensal bacteria -- "good" microbes that, among other functions, help the body digest food. The gastrointestinal tract contains literally trillions of such cells, and yet the immune system seemingly turns a blind eye. However, in several chronic human diseases such as inflammatory bowel disease (IBD), HIV/AIDS, cancer, cardiovascular disease, and diabetes, the immune system attacks these normally beneficial bacteria, resulting in chronic inflammation and contributing to disease progression.

Now, researchers may finally understand an important mechanism that keeps this friendly truce intact -- a finding that may lead to the development of new therapeutic strategies for such chronic diseases.

Gregory F. Sonnenberg, PhD, research associate in the Department of Medicine, Gastroenterology Division, and the Institute for Immunology at the Perelman School of Medicine, University of Pennsylvania, with postdoctoral researcher Matthew Hepworth, PhD, report in Nature that innate lymphoid cells (ILCs) directly limit the response by inflammatory T cells to commensal bacteria in the gut of mice. Loss of this ILC function effectively puts the immune system on an extended war footing against the good, commensal bacteria -- a condition observed in multiple chronic inflammatory diseases.

ILCs are a class of rare immune cells that were first described a few years ago. Previous research has implicated these cells in regulating immune responses in the intestine, mostly through their ability to secrete immune-activating cytokines. But until now, researchers have had a hard time studying ILCs because it hasn't been possible to selectively eliminate them in the context of an otherwise intact immune system.

Sonnenberg, Hepworth, and their colleagues deleted a protein called RORγt, required for one class of ILCs, in mice. RORγt-deficient animals had exacerbated T cell responses against commensal bacteria and systemic inflammation. In contrast, deletion of previously identified ILC effector cytokines such as IL-22 and IL-17 did not elicit an immune response to commensal bacteria, suggesting the ILCs use an unidentified regulatory pathway.

When the team looked at what gene signatures the RORγt-dependent ILCs expressed, they found high expression of major histocompatibility complex class II (MHCII) protein, which some cells use to display foreign proteins to the immune system and directly interact with T cells.

This, as with RORγt-deficient mice, selective deletion of MHCII in ILCs resulted in hyperactive T-cell responses directed against commensal bacteria and systemic inflammatory responses, all of which could be alleviated by depletion of commensal bacteria with broad-spectrum antibiotics. What's more, mice with the selective deletion of MHCII in ILCs also developed inflammatory bowel disease, which was driven by aberrant CD4+ T-cell responses to commensal bacteria.

This study is the first to selectively target ILCs in the presence of an intact immune system, and these findings suggest that under normal conditions, ILCs play a critical role in dampening the anti-bacterial T-cell response using MHCII. Indeed, when Sonnenberg's team looked at ILC activity directly, they found that MHCII+ ILCs could present foreign antigen to T cells and limit their expansion and pro-inflammatory properties.

Essentially, ILCs seem to instruct T cells to trust -- that is, ignore -- commensal bacteria, thereby allowing the immune system to coexist with these foreign entities. Loss or dysregulation of ILCs, in turn, brought on by genetic or environmental factors such as diet or infection, for example, eliminates that protective action. This can lead to dysregulated immune activity and chronic inflammation.

"Inappropriate immune response to commensal bacteria and subsequent pathologic inflammation is a contributing factor to the pathogenesis and progression of many chronic human diseases, including inflammatory bowel disease, HIV/AIDS, viral hepatitis, cancer, cardiovascular disease, and diabetes," says Sonnenberg.

"This study provides new insight into the pathways that regulate immune responses to commensal bacteria and maintain tissue homeostasis" adds Hepworth.

Importantly, the study also identifies that MHCII+ ILCs are found in the intestinal tissues of healthy human donors. "Although it's still early days for this line of research, these findings provoke the hypothesis that MHCII+ innate lymphoid cells may be an important pathway to therapeutically target in the treatment of some chronic inflammatory diseases," suggests Sonnenberg. The Sonnenberg lab is now trying to establish if that is the case.

Other Penn coauthors include Laurel Monticelli, Thomas Fung, Stephanie Grunberg, Rohini Sinha, Adriana Mantegazza, Alison Crawford, Jill Angelosanto, E. John Wherry, Frederic Bushman, and David Artis.

The research was funded by the National Institutes of Health (AI061570, AI087990, AI074878, AI095776, AI102942, AI095466, AI095608, AI097333, T32-AI055428, DK071176, DP5OD012116), the Crohn's and Colitis Foundation of America, and the Burroughs Wellcome Fund.


Story Source:

The above story is based on materials provided by Perelman School of Medicine at the University of Pennsylvania. Note: Materials may be edited for content and length.


Journal Reference:

  1. Matthew R. Hepworth, Laurel A. Monticelli, Thomas C. Fung, Carly G. K. Ziegler, Stephanie Grunberg, Rohini Sinha, Adriana R. Mantegazza, Hak-Ling Ma, Alison Crawford, Jill M. Angelosanto, E. John Wherry, Pandelakis A. Koni, Frederic D. Bushman, Charles O. Elson, Gιrard Eberl, David Artis, Gregory F. Sonnenberg. Innate lymphoid cells regulate CD4 T-cell responses to intestinal commensal bacteria. Nature, 2013; DOI: 10.1038/nature12240

Cite This Page:

Perelman School of Medicine at the University of Pennsylvania. "How immune system peacefully co-exists with 'good' bacteria." ScienceDaily. ScienceDaily, 22 May 2013. <www.sciencedaily.com/releases/2013/05/130522130951.htm>.
Perelman School of Medicine at the University of Pennsylvania. (2013, May 22). How immune system peacefully co-exists with 'good' bacteria. ScienceDaily. Retrieved October 21, 2014 from www.sciencedaily.com/releases/2013/05/130522130951.htm
Perelman School of Medicine at the University of Pennsylvania. "How immune system peacefully co-exists with 'good' bacteria." ScienceDaily. www.sciencedaily.com/releases/2013/05/130522130951.htm (accessed October 21, 2014).

Share This



More Health & Medicine News

Tuesday, October 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) — The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Vaccine Trials to Start a in January

WHO: Ebola Vaccine Trials to Start a in January

AP (Oct. 21, 2014) — Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe in soon to start trials, the World Health Organization said Tuesday. (Oct. 21) Video provided by AP
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) — A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
CDC Issues New Ebola Guidelines for Health Workers

CDC Issues New Ebola Guidelines for Health Workers

Reuters - US Online Video (Oct. 21, 2014) — The U.S. Centers for Disease Control and Prevention has set up new guidelines for health workers taking care of patients infected with Ebola. Linda So reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins